GBS Inc.

Greetings and thank you for joining us for GBS Inc.' 's fourth quarter and fiscal year end 2022 financial and business update conference call. Currently, all participants are in a listen-only mode. A question and answer session will follow the formal presentation. As a reminder, today's conference call is being recorded. Joining us on the call today are Dr. Stephen Boyages, GBS CEO and Chairman of the Board, and Spiro Sekiris, Chief Financial Officer. A press release announcing financial results and providing a business update was issued this afternoon and is available on the GBS website at gbs.inc. If you would like to be added to the company distribution list, please send an email to investor.relation at gbs.inc. Some of the statements on this conference call are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934, and the Private Security Litigation Reform Act of 1995, which involves risks and uncertainties. Forward-looking statements on this call include, without limitation, GBS Inc.' 's ability to develop and commercialize a diagnostic test, realize commercial benefit from its partnerships and collaborations, and secure regulatory approval, among others. Although GBS Inc. believes that the expectations reflected in such forward-looking statements are reasonable as of the date made, exceptions may prove to have been materially different from the results expressed or implied by such forward-looking statements. GBS Inc. has attempted to identify forward-looking statements by terminology, including belief estimates, anticipates, expects, plans, projects, intents, potential, may, could, might, will, should, approximately, or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. These statements are only predictions and involve known and unknown risks, uncertainties, and other factors included in the company's public filings filed with the Securities and Exchange Commission. Any forward-looking statements contained in this release speak only as of its date. We undertake no obligation to update any forward-looking statements contained in this release to reflect events or circumstances occurring after its date or to reflect the occurrence of unanticipated events. During this conference call, the company may refer to EBITDA, a non-GAAP measure. EBITDA is not and should not be considered an alternative to net income loss from operations and or other measures for determining operating performance. EBITDA is normally calculated by adding back income tax, depreciation, and amortization to net income loss. I would now like to turn the floor over to Dr. Stephen Boyages, CEO of GBS, Inc. Stephen, please go ahead.

Thank you, Operator, and good afternoon, everyone. We appreciate you joining us today for our fiscal year-end and fourth quarter 2022 financial and business update call. Hopefully you've had the opportunity to review today's corresponding press release, providing an overview of our recent achievements, important upcoming milestones and financial results for the fourth quarter ended June 30, 2022. On today's call, I would like to point out the accomplishments of this most recent quarter, as well as reflect on all we've achieved over the last 12 months. I'd also like to provide an update on our exciting ongoing engagement with Intelligent Fingerprinting Limited for the rights to its point-of-care fingerprint sweat-based drug screening technology, presently focused on opioids and drugs of abuse. I will then turn the call over to Spiro, our Chief Financial Officer, for a review of key financial metrics, including our preliminary year-end and fourth quarter results with updated forecasted cash burn. Following a reshuffling of roles early in the year, including my appointment as CEO and chair of the board, the entire GBS team has successfully achieved several key milestones previously forecasted. Specifically, as it relates to the saliva glucose biosensor as our lead asset, and following IRB approval received in March, we've now completed sample collection and analysis in our study of coincident sampling of oral fluid and blood to evaluate the time course of glucose. This study enrolled approximately 40 adults with type 2 diabetes mellitus at the Diabetes Research Institute of Sutter Health's Mills Peninsula Medical Center in San Mateo, California. It has been conducted to support clinical validation whilst also solidifying the direction of future clinical studies. I'm pleased to report that the results from that study were encouraging and in line with expectations where blood, salivary glucose concentrations were consistent with previous studies. Work is now underway to refine the sampling protocols and establish a greater body of statistics. Meanwhile, we are moving into the final design and verification phase of glucose biosensor development involving two key parallel clinical studies. The first of these studies will focus on eliminating variables affecting glucose levels in saliva and in the sample collection method. The second study will specifically examine saliva detection on the glucose biosensor test strip to assess accuracy and reproducibility. Both studies will further improve saliva collection protocols and fine-tune the biosensor performance as we head towards finalizing our product design and moving it from research and development into manufacturing. With clinical development and regulatory dialogue proceeding at pace, we are concurrently establishing the manufacturing capacity to support further studies and prospective commercial supply. In June, we excitedly announced the selection of a site at the University of Newcastle in Australia for construction and operation of a new state-of-the-art proprietary biosensor manufacturing facility The company anticipates construction commenced before end of calendar year 2022. To add to this, our first batch of new equipment arrived on site with the next installment of delivery scheduled to arrive before end of September. This includes a new ink delivery system and a UV water purification system, both central for the biosensor production. We have also ordered a new inductively coupled plasma mass spectrometer, which we expect delivery early in the new year. This equipment is vital when looking to improve the overall performance and reproducibility of the biosensor. By year end, we anticipate 60% of the equipment to have been delivered, with the remaining 40% due early in the new year. Concurrently, and while we continue to advance our saliva glucose biosensor effectively, not only for glucose detection and diabetes, but also with research to develop new biosensors for hormone, tumor, and allergen biomarkers, we are equally dedicated to exploring all opportunities to build out synergies for GBS business overall. Hence why we've been in active engagement with intelligent fingerprinting regarding its point of care fingerprint sweat-based drug screening technology focused on opioids and drugs of abuse. In June of this year, we announced the execution of an exclusivity agreement with IFP for its fingerprint sweat-based drug testing technology. This agreement represents the precursor for a proposed acquisition of IFP that if consummated, would allow GBS to further solidify its leadership position in the rapid non-invasive diagnostic solutions, accelerate revenue growth, and expand our portfolio of tests. We continue to see this as a prime and seminal opportunity for GBS' future growth and success, and look forward to updating the market accordingly. Before I turn the call over to Spiro to discuss our financials, I would also like to welcome Peter Passaris as GBS' new Director of Operations. Originally from the US, Peter and his family recently relocated to Sydney. And with 18 years of manufacturing and enterprise experience, Peter is exceptionally qualified to manage our Newcastle SRA and product development activities. He joined us most recently from Ecolab, where he served as sales and operations manager, prior to which he worked as a chemical engineer in R&D before eventually moving into technical sales and operations. So with a warm welcome to Peter. I would now like to turn the call over to our CFO, Spiro Securus, for a more detailed review of our third quarter financials. Thank you, Spiro.

Thank you, Stephen.